ClinicalTrials.gg
RecruitingNCT06205979Updated Jan 16, 2024

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

An Early Phase 1 interventional study of Ranibizumab Injection [Lucentis] and Aflibercept Injection [Eylea] in Diabetic Macular Edema, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Sohag University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.

Planned enrollment
8th of 17
50 · median 50
Started
2023
with 2 others
Phase 1
2 of 22
2 open now
Registered
17th of 22
by date

Among the 22 studies in Macular Edema with a site in Egypt, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 1, and was the 17th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Edema with a site in Egypt, or all of them as a file.
02

Study summary

Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR . Retinal oedema is responsible for retinal micro-structural alterations, retinal atrophy of photoreceptors and ganglion cell disorders . In addition, it might be considered consensual that the best improvements in VA could be accomplished when retinal oedema is managed. In the context of a chronic and progressive disease, DME has to be faced as a state to control as effectively and rapidly as possible . Vascular endothelial growth factor (VEGF) is a protein that promotes the growth of new blood vessels. It also makes the blood vessels more leaky. Anti- VEGF medicines stop the growth of these new blood vessels. This prevents damage to the retinal light receptors and loss of central vision. The DME treatment has been shifted from the laser photocoagulation to anti-VEGF therapy . The advantages of anti-VEGF therapy in decreasing DME and improving patient's vision have been reported in many studies . Ranibizumab, in addition to aflibercept, have been reported as the first line therapies among the other anti-VEGF . There are several data demonstrating the efficiency of ranibizumab in treatment of patients with DME . On the other hand, there are studies that revealed poor response of some patients to anti-VEGF therapies even after 3 or more injections Non-modifiable risk factors for diabetic retinopathy are gender and DM duration.

Modifiable risk factors contributing to the development of diabetic retinopathy are elevated blood sugar levels, blood pressure, and dyslipidemia which is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetic . Hard exudates are thought to be induced by the leakage of lipids from dysfunctional retinal capillaries . Therefore, theses were formulated that higher levels of total cholesterol, LDL-C and triglycerides could be considered biomarkers of the development of hard exudates in DM patients . Aim of the work

  • Correlate between dyslipidemia and the response of patients with diabetic macular oedema to intravitreal anti-VEGF injection
03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with type II DM and center involving DME with central foveal thickness more than 280 um.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of macular ischemia
  2. Evidence of macular traction
  3. Previous intravitreal injections
  4. Previous macular laser therapy
  5. Previous pars plana vitrectomy
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Interventions

  • DrugRanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.

06

What researchers measure

Primary outcomes

  1. change in the best corrected visual acuity in meters

    measure of the ability of the eye to distinguish shapes and the details of objects at a given distance with the help of corrective lenses

    Time frame: 2 months

  2. change in the retina and macula measurements by Optical coherence tomography (OCT)

    assess the state of the retina and macula by measuring : * Average Thickness in (μm)

    Time frame: 2 months

  3. change in the retina and macula measurements by Optical coherence tomography (OCT)

    assess the state of the retina and macula by measuring : * Center thickness in (μm)

    Time frame: 2 months

  4. change in the retina and macula measurements by Optical coherence tomography (OCT)

    assess the state of the retina and macula by measuring : * Total volume in (mm3)

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Abramoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018 Aug 28;1:39. doi: 10.1038/s41746-018-0040-6. eCollection 2018. PubMed 31304320 ↗
  • Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016 Mar;134(3):278-85. doi: 10.1001/jamaophthalmol.2015.5346. PubMed 26746868 ↗
  • Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol. 2016 Dec;100(12):1596-1604. doi: 10.1136/bjophthalmol-2016-308388. Epub 2016 May 26. PubMed 27231313 ↗
  • Katz G, Moisseiev E, Goldenberg D, Moisseiev J, Lomnicky Y, Abend Y, Treister G, Levkovitch-Verbin H. Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Eur J Ophthalmol. 2017 Mar 10;27(2):210-214. doi: 10.5301/ejo.5000838. Epub 2016 Jul 18. PubMed 27445070 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2024, 6 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2024
First posted
Jan 16, 2024
StartActual
Dec 12, 2023
Primary completionEst.
Jun 14, 2024
CompletionEst.
Jun 14, 2024
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205979
Lead sponsor
Sohag University
Responsible party
Ola Gamal Amin (resident of ophthalmology at el Helal hospital, Sohag University) — Principal investigator
First posted
Jan 16, 2024
Start date
Dec 12, 2023
Primary completion
Jun 14, 2024 (estimated)
Completion
Jun 14, 2024 (estimated)
Last update
Jan 16, 2024

Study contacts

Ola G Ameen, resident
Contact
ola011117@med.sohag.edu.eg
01009507654
. Khulood M Mahmood, professor
Contact
01001173960

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion